Primex Pharmaceuticals Appoints Ernesto Alegria as CFO

Wednesday, August 17th 2016 at 6:00am UTC

ZUG, Switzerland–(BUSINESS WIRE)– Swiss pharmaceutical company Primex Pharmaceuticals AG announces the
appointment of Ernesto Alegria as Chief Financial Officer. On August
13th, 2016, he joined Primex Pharmaceuticals’ Executive Management Team.

This Smart News Release features multimedia. View the full release here:
http://www.businesswire.com/news/home/20160816005755/en/

Ernesto Alegria (Photo: Business Wire)

Most recently, Ernesto Alegria worked for Acino Group as Group CFO. His
responsibilities included delisting the company from the Swiss Stock
Exchange, a number of M&A transactions and developing Acino Group into a
fast growing mid-size pharmaceutical company.

Prior to Acino, Mr. Alegria was Head of Business Controlling and Finance
for the emerging markets of Takeda Pharmaceuticals International GmbH.
Previously, he held senior financial and commercial roles with Nycomed
and Norske Skog.

This follows the announcement in February 2016, that Primex
Pharmaceuticals had acquired the global rights for an advanced oral
pharmaceutical candidate for pediatric anesthesiology developed by
Advicenne. With this acquisition, Primex Pharmaceuticals expanded its
portfolio with a unique product that will be distributed through
Primex’s existing and new partners. The market potential is evaluated as
hundreds of millions of euros.

PANU PAAPPANEN, Chairman of the Board and Owner, commented: « Mr.
Alegria has gained considerable relevant experience in the
pharmaceutical industry. His strong financial control, market knowledge
and transaction experience will be a considerable asset for Primex.”

KARI SARVANTO, President and Co-Founder of Primex Group, added:
“I am delighted that we can attract a highly talented professional as
Ernesto Alegria to our team to help us build sustainable growth.”

About Primex Pharmaceuticals

Primex Pharmaceuticals is a fast growing global specialty company
spearheading a new lean pharmaceutical business model.

Primex aims to become the leading global innovative Anesthesia company
helping patients undergo a wide range of medical procedures. With a
portfolio of strong, trusted anesthesia products including Recofol N
(propofol) acquired from Bayer, and the recent acquisition of a novel,
oral solution pharmaceutical candidate for pediatric anesthesiology from
Advicenne, Primex Pharmaceuticals will continue to identify and acquire
new medications that complete the ‘Triad of Anesthesia’.

Primex Pharmaceuticals’ global partner network operates in over 40
countries and reaches a population of nearly one billion. The company is
headquartered in Zug, Switzerland; all Primex products are manufactured
in the EU. Primex Pharmaceuticals has proven underlying business
operations and historically strong revenue growth.

See more at www.Primexpharma.com